484
Participants
Start Date
April 30, 2007
Primary Completion Date
September 30, 2010
Study Completion Date
July 31, 2013
Carboplatin
Carboplatin was provided as commercially available drug.
Gemcitabine
Gemcitabine was provided as commercially available drug.
Bevacizumab
Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Placebo
Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Lead Sponsor
Genentech, Inc.
INDUSTRY